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Background: The Malaysian Tualang honey (TH) is not only cytotoxic to human breast cancer cell lines but it has
recently been reported to promote the anticancer activity induced by tamoxifen in MCF-7 and MDA-MB-231 cells
suggesting its potential as an adjuvant for the chemotherapeutic agent. However, tamoxifen produces adverse effects
that could be due to its ability to induce cellular DNA damage. Therefore, the study is undertaken to determine the
possible modulation of the activity of 4-hydroxytamoxifen (OHT), an active metabolite of tamoxifen, by TH in
non-cancerous epithelial cell line, MCF-10A, in comparison with MCF-7 cells.
Methods: MCF-7 and MCF-10A cells were treated with TH, OHT or the combination of both and cytotoxicity and
antiproliferative activity were determined using LDH and MTT assays, respectively. The effect on cellular DNA integrity
was analysed by comet assay and the expression of DNA repair enzymes was determined by Western blotting.
Results: OHT exposure was cytotoxic to both cell lines whereas TH was cytotoxic to MCF-7 cells only. TH also significantly
decreased the cytotoxic effect of OHT in MCF-10A but not in MCF-7 cells. TH induced proliferation of MCF10A cells but
OHT caused growth inhibition that was abrogated by the concomitant treatment with TH. While TH enhanced the
OHT-induced DNA damage in the cancer cells, it dampened the genotoxic effect of OHT in the non-cancerous cells. This
was supported by the increased expression of DNA repair proteins, Ku70 and Ku80, in MCF-10A cells by TH.
Conclusion: The findings indicate that TH could afford protection of non-cancerous cells from the toxic effects of
tamoxifen by increasing the efficiency of DNA repair mechanism in these cells.
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Chemotherapeutic agents effectively kill most of the can-
cer cells. However, cellular specificity of those drugs re-
mains a major obstacle where side effects often develop as
a result of the drugs’ action on the normal cells and tis-
sues. Tamoxifen is commonly used to treat breast tumors
that are classified as estrogen receptor positive (ER+) since
the 1980s [1,2]. It blocks the estrogenic effects responsible
for growth and proliferation of breast cancer cells. How-
ever in certain cases, breast cancer patients present with
intrinsic resistance to tamoxifen treatment [3] and in-
creasing the dose will only lead to the problem of undesir-
able effects to the patients as a result of the drug action on* Correspondence: niksoriani@usm.my
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article, unless otherwise stated.normal tissues and cells. These include endometrial cancer
risk [4], risk of liver cancers [5] and effect on eyesight [6].
Chromosomal aberrations and DNA damage have also
been reported in several cell types and animal organs
[7-9]. Tamoxifen undergoes metabolic reactions involving
the cytochrome P450 enzyme family and lack of this en-
zyme family was suggested to lead to tamoxifen resistance
of the cancer cells [10].
Honey is a natural product containing a complex mix-
ture of sugars, minerals, proteins, vitamins, organic acids,
flavonoids, phenolic acids, enzymes and other phytochem-
icals. It contains antioxidant molecules such as flavonoids,
phenolic acids, catalase, carotenoids, peroxidase and cata-
lase [11]. Honey’s many potential health benefits haveentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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for various ailments by the general public [12]. Research
has shown that honey is capable of inhibiting the
growth of bladder cancer cell lines and is effective
against murine bladder cancer implantation [13]. More
recently, a Nigerian jungle honey displayed antitumour
activity in mice inoculated with Lewis Lung Carcinoma
cells [14] and Manuka honey inhibited the prolifera-
tion of murine melanoma, colorectal carcinoma and
breast cancer cells as well as tumour growth in a mel-
anoma tumour model [15]. Tualang honey (TH) is a
wild multifloral Malaysian honey produced by Apis
dorsata (Asian giant bees) that build their hives high
up in the Tualang tree (Koompassia excelsa). We have
recently shown that TH could inhibit growth of breast
cancer cells, MCF-7 and MDA-MB-231, by inducing
apoptosis [16] and promoted the anticancer effects of
tamoxifen on these cells [17]. However, TH was ob-
served to be noncytotoxic to the noncancerous breast
epithelial cells, MCF-10A [16]. The present study was
therefore carried out to further understand the differen-
tial effects of TH on MCF-7 and MCF-10A cells and to
determine its influence on the activity of the tamoxifen
metabolite, 4-hydroxytamoxifen (OHT) in these cells.Methods
Cell culture and treatment
MCF-10A cell line was purchased from the American
Type Culture collection and maintained in complete
growth medium consisting of 1:1 mixture of Dulbecco’s
modified Eagle’s medium and Ham’s F12 medium supple-
mented with 5% fetal bovine serum, 20 ng/ml epidermal
growth factor, 10 μg/ml insulin, 500 ng/ml hydrocortisone
and 1 unit/ml penicillin/streptomycin. TH was supplied
by the Federal Agricultural Marketing Authority Malaysia.
This type of honey is produced by Asian giant bees (Apis
dorsata) that built their hives on Tualang trees (Koompas-
sia excels) in the Malaysian jungle. Prior to cell treatment,
the TH was freshly prepared by dissolving it in serum-free
culture medium at a final concentration of 10% (v/v) and
then was filter-sterilized using 0.22 μm syringe filter unit
(Millipore, USA). The tamoxifen metabolite, OHT, was
obtained from Sigma-Aldrich®, dissolved in ethanol and
stored at −20°C in aliquots. Cells were treated with OHT,
TH or their combination for up to 72 hr.
Cytotoxicity assay
Cells were seeded in 24-well cell culture plates (Nunc,
Denmark) at a density of 1 × 105 cells/ml in a complete
growth medium for 24 hr at 37°C in a humidified incuba-
tor. The culture medium was replaced with assay medium
(2% fetal bovine serum and without epidermal growth fac-
tor) prior to treatment with TH (1%), OHT (10 or 15 μM)or their combination for up to 72 hr. Culture cell super-
natants (100 μl) were transferred into a 96-well micro-
plate and the cytotoxicity was assessed using Lactate
Dehydrogenase (LDH) Cytotoxicity Detection Kit (Roche,
Germany) according to the manufacturer’s instructions.
Proliferation assay
Cells were seeded in a 96 well plate at a density of 2 × 104
cells per well and treated with 1% TH, 10 μM OHT,
15 μM OHT and their combination for 24 and 48 hr. At
the end of treatment, 20 μl of MTT (5 mg/ml) was added
to each well and the plate was incubated for 4 h at 37°C
with 5% CO2. The medium was then aspirated and 100 μl
of DMSO was added to each well to dissolve the tetrazo-
lium crystals produced by viable cells. Absorbance was
measured using a plate reader (VersaMax, Molecular De-
vices, US) at 540 nm wavelength.
Comet assay
Cells were seeded as above and treated with TH (1%),
OHT (10 μM) and their combination of both for 24 hr.
Cells were then collected by trypsinisation and washed
with PBS. Comet assay analysis was performed by using
Trevigen’s Commet Assay® kit (Trevigen, Inc) according
to the manufacturer’s instructions. Briefly, cell pellets
were mixed with low melting point agarose at a ratio of
1:10 (v/v) and pipetted onto the CometSlide™. Cells were
then lysed in the lysis solution before been treated with
alkali solution in order to unwind and denature the DNA
and hydrolyze sites of damage. The samples were then
electrophoresed, stained with a fluorescent DNA intercal-
ating dye (SYBR® green 1) and visualized under fluores-
cence microscope (Nikon, Tokyo, Japan) using a band
pass FITC filter (excitation 490 nm, emission >520 nm).
Fifty cells were randomly selected and captured per sam-
ple using 100× magnification and were analyzed by using
Comet Image Analysis System software (CometScores
software; TriTek, Sumerduck, VA, USA) that is available
at http://www.autocomet.com/products_cometscore.php.
Tail length, % of DNA in the tail and Olive moment were
used as evaluation of the DNA damage.
Western blotting
Cells cultured in 75 cm2 flasks at a density of 1 × 106 cells/
ml were treated with TH (1%), OHT (10 μM) or their com-
bination for 24 hr. Cell were lysed in 150 μl lysis buffer
(50 mM of Tris–HCl, 150 mM of NaCl, 0.2% SDS, 1 mM
PMSF, 2 μg/ml of leupeptin, 2 μg/ml of aprotinin and
1 mM of Na3VO4) and the lysates were obtained by centri-
fugation at 12,000 rpm for 2 min at 4°C. The protein con-
centrations were determined using a spectrophotometer
(NanoDrop) at 280 nm absorbance. For western blot
analysis, 100 μg of protein was resolved on 10% SDS-
polyacrylamide gel for 1 hr followed by semi-dry transfer
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milk diluted in the TBS-Tween 20. Next, the membrane
was washed with TBS-Tween20 and incubated with
the primary antibody (Rad 51, Ku70/Ku80 and β-actin;
Abcam, USA) overnight at 4°C. After washing with TBS–
Tween 20, the membrane was incubated with secondary
antibody conjugated with horseradish peroxidase for 1 hr
at room temperature. Antibody binding was detected by
incubating the membrane with ECL™ Prime Western Blot-
ting reagent according to the manufacturer’s protocols
and visualized using an image analyzer under chemilumin-
escence filter. The band density for each treatment com-
pared to control was analyzed using ImageJ 1.46 software
(http://imagej.nih.gov/ij/) and the values were normalized
to the β-actin band density.
Statistical analysis
Triplicates of three independent experiments were carried
out and data are expressed as the mean ± SD. Differences
between the groups were evaluated by using Student T-
test or one-way analysis of variance (ANOVA) followed by
post hoc Tukey multiple comparison test with the aid of







































Figure 1 Cytotoxicity of TH and OHT on MCF-7 and MCF-10A cells. M
TH (1% v/v) and their combination for up to 72 hr and cell death was dete
three independent experiments. Statistical significance was determined by
Ωp < 0.01 for TH + OHT compared to OHT; *p < 0.05, **p < 0.01 compared tResults and discussion
Various studies have recently been conducted to explore
the medicinal benefits of Tualang honey and findings have
shown that TH has significant anticancer activity against
human cancer cell lines such as breast, cervical [16], oral
and osteosarcoma [18]. Cancer cell death by TH occurs via
induction of caspase-dependent apoptosis [16]. Recently,
7,12-dimethylbenz [a] anthracene (DMBA)-induced breast
tumours in TH-treated rats were reported to be much less
in number, volume and weight with better histological
grade and morphology compared to the non-honey treated
rats [19]. The anticancer activities showed by TH could be
attributed to its antioxidant property as shown by the high
total phenolic content and total antioxidant activity based
on the ferric reducing ability of plasma (FRAP) assay [20].
Other than phenolic compounds, peptides, organic acids,
enzymes and other minor components could also contrib-
ute to the antioxidant capacity of honey [11].
Tamoxifen is widely used as an antioestrogen for
treatment of breast cancer [21] but several side effects
have been noted including increased endometrial and
colorectal cancer risk reviewed in [22] that could be attrib-
uted to the drug’s ability to form DNA adducts through α-
hydroxylation of the parent molecule and its metabolites24hr
 48hr
 72hr















CF-7 (A) and MCF-10A (B) cells were treated with OHT (10 and 15 μM),
rmined using LDH assay. Each value represents the mean ± SD from
using the Student T test. Ψp < 0.05 for TH + OHT compared to TH;
o untreated cells.
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peutic agents have led to the search and development of
new antitumor candidates or adjuvants. However in many
cases non-cancerous cells often are not tested alongside
the cancerous cells. The idea that TH activities could pos-
sibility be selective against cancerous cells came from an
initial study which showed that human breast carcinoma
cell lines, MCF-7 and MDA-MB-231, were highly sensitive
to TH while the non-cancerous MCF-10A breast epithelial
cells were not affected [16]. The present study was there-
fore carried out to further understand the differential effects
of TH on MCF-7 and MCF-10A cells and to determine its
influence on the activity of OHT in these cells. The dose of
honey selected was based on our previously published con-
centration that caused apoptosis as well as promotion of
tamoxifen-induced apoptosis of MCF-7 cells [17]. The con-
centration of OHT chosen was within the ranges reported
in the literature for breast cancer cells including MCF-7
[25,26].
Both TH (1%) and OHT (10 μM) were found to be cyto-
toxic to MCF-7 cells with the latter being more effective
with longer treatment duration (Figure 1A). In line with
our previous findings of increased apoptosis with the com-
bination of TH and tamoxifen [17], the current study also
shows that TH promoted the cytotoxic effect of the tam-
















































Figure 2 Proliferation of MCF-7 and MCF-10A cells induced by TH and
(10 and 15 μM), TH (1%) and their combination for up to 48 hr followed by
normalized against the respective control (taken as 100%). Statistical signifi
OHT compared to TH; Ψp < 0.01 for TH + OHT compared to OHT; *p < 0.05,from 25.2% to 38.9% within 24 hr. At 15 μM concentra-
tion, OHT was also cytotoxic to the non-cancerous MCF-
10A cells and the effect increased with exposure time
causing 70.1% cell death after 72 hr (Figure 1B). This is in
agreement with the report of Petinari et al. [27] where
tamoxifen was found to be cytotoxic to both cancerous
and non-cancerous cell lines at micromolar concentrations
and was in fact reported to be more aggressive in the non-
cancerous cells. This was thought to be due to the higher
expression of estrogen receptor by these non-cancerous
cells. Interestingly, rather than promoting OHT’s activity as
observed with the MCF-7 cells, TH significantly amelio-
rated the cytotoxic effect of the antioestrogen in MCF-10A
cells at all time points (Figure 1B) suggesting TH’s protect-
ive effect in non-cancerous cells. The cytotoxicity results
observed are supported by the findings of the MTT assay
(Figure 2). TH was found to markedly increase the prolifer-
ation of MCF10A cells while not significantly affecting the
proliferation of MCF-7 cells. OHT on the other hand, re-
duced the proliferation of MCF-10A cells but the presence
of TH partially abrogated this inhibition. Proliferation of
MCF-7 cells was not significantly modulated by all
treatments. Tamoxifen induces chromosomal breaks [7]
and is genotoxic to both normal lymphocytes and breast
cancer cells [9]. Formation of DNA single- and double-
strand breaks and oxidative modifications of purines 24hr
48hr
10 OHT15 TH+OHT15 UN
T10 OHT15 TH+OHT15 UN
**
**
OHT. MCF-7 (A) and MCF-10A (B) cells were treated with OHT
an MTT assay. Each value represents the mean ± SD that has been
cance was determined by using the Student T test. Ψp < 0.01 for TH +
**p < 0.01 compared to untreated cells.
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free radical generation [9].
In the current study, comet assay was performed to
evaluate total cellular DNA damage. A suboptimal concen-
tration (10 μM) of OHT was used for the comet assay so
that at least the required 90% living cells were present to
avoid false positive results (according to the manufacturer’s
recommendations). Assessment of percentage of DNA in
the comet tail, the tail length and Olive moment show that
OHT induced significant DNA damage in MCF-7 cells
(Figure 3) as well as MCF-10A cells (Figure 4), indicating
that accumulation of DNA damage is involved in OHT-
induced cytotoxicity in both cancerous and non-cancerous
cell lines. OHT was found to be more genotoxic to MCF-





























































Figure 3 DNA damage induced by TH and OHT in MCF-7 cells. Comet
TH (1%) and their combination for 24 hr. Cells were stained with SYBR Gree
Percentage of DNA in the tail (A), tail length (B) and Olive moment (C) we
means ± SD from three independent experiments. Cells were observed und
using one-way ANOVA followed by post hoc Tukey multiple comparison te
compared to OHT; *p < 0.05, **p < 0.01 compared to untreated cells.27.2% and 15.8%, respectively. MCF-10A cells also dis-
played higher values of tail length and Olive moment. On
the other hand, TH induced DNA damage only in MCF-7
cells and did not affect the integrity of DNA in MCF-10A
cells.
We then show that the combination of OHT and TH
promoted more extensive DNA damage in the cancerous
MCF-7 cells as reflected by the significantly higher per-
centage of DNA in the tail of the comet (increased from
15.8 to 26.1%), as well as the increased tail length and olive
moment compared to OHT treatment alone (Figure 3). In
contrast, TH significantly reduced the DNA damage in-
duced by OHT (reduced from 27.2 to 9.6%) in MCF-10A
cells (Figure 4). Wozniak et al. [9] reported that DNA
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assay was performed following treatment of cells with OHT (10 μM),
n and analyzed using Comet Image Analysis System software.
re used as evaluation of DNA damage. The values are presented as
er fluorescence microscopy (D). Statistical analysis was determined
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Figure 4 DNA damage induced by TH and OHT in MCF-10A cells. Comet assay was performed following treatment of cells with OHT
(10 μM), TH (1%) and their combination for 24 hr. The cells were stained with SYBR Green and analyzed using Comet Image Analysis System
software. Percentage of DNA in the tail (A), tail length (B) and Olive moment (C) were used as evaluation of DNA damage. The values are
presented as means ± SD from three independent experiments. Cells were observed under fluorescence microscopy (D). Statistical analysis was
determined using one-way ANOVA followed by post hoc Tukey multiple comparison test. Ψp < 0.05 for TH + OHT compared to TH; Ωp < 0.01 for
TH + OHT compared to OHT; **p < 0.01 compared to untreated cells.
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cause of less effective repair mechanisms. Long-term ex-
posure to this drug may therefore induce mutations in
critical genes especially those involved in the DNA repair
pathways. Repair of DNA lesions is therefore critical for
the cell to preserve the integrity of its genomic and incom-
plete repair could later lead to malignant transformation
[28,29]. According to Ellsworth et al. [30], genetic abnor-
malities have been observed in histologically normal epi-
thelial cells surrounding breast carcinomas and that
abnormalities of tumourigenic importance could accumu-
late in these cells. It could therefore be inferred from the
current findings that TH may have the ability to repair
and/or preserve genomic stability in the normal cells.We further examined whether differences in DNA dam-
age effects in the cancerous and non-cancerous cells
induced by TH is associated with modulation of the ex-
pression of Rad51, Ku70 and Ku80 enzymes which are in-
volved in the repair of DNA double strand breaks. Rad51
plays a role in the strand break repair through homologous
recombination while Ku70 and Ku80 are involved in non-
homologous end joining repair pathway without the re-
quirement for a homologous template [31]. Although they
both form a heterodimer, it is possible that they function
independently [32]. Inability to repair DNA damage could
lead to genetic instability or mutation or chromosomal ab-
erration that could enhance cancer development [31]. Ana-
lysis of more than 100 tumour specimens revealed that
UT UT
MCF-10A


















Figure 5 Expression of DNA repair enzymes in MCF-7 and MCF-10A cells treated with TH and OHT. The expression of Rad51, Ku70 and
Ku80 in the cells was determined by Western blotting following 24 hr exposure to OHT (10 μM), TH (1%) or their combination. The protein bands
were visualized using an image analyzer and band density was analysed using ImageJ software with fold-change difference of expression
compared to untreated cells (UT) written below each band.
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mammary tumour grading and is considered as a poten-
tial biomarker for diagnosis and prognosis of invasive
ductal mammary carcinoma [33]. In a study conducted
by Pucci et al. [34], Ku70 and Ku80 heterodimer binding
activity and the heterodimer DNA repair capability were
reduced in advanced breast and bladder tumours [34].
Our results show that Rad51 protein was not upregu-
lated by either OHT or TH alone or their combination in-
dicating a non-significant role of this repair enzyme. In
contrast, both OHT and TH increased Ku70 (2.40- and
2.67-fold, respectively) and Ku80 (1.89- and 1.69-fold, re-
spectively) expression in MCF-7 cells. However in MCF-
10A cells, a marked overexpression of Ku70 (3.32-fold) and
Ku80 (2.35-fold) was observed following TH treatment but
not by OHT (Figure 5). The presence of TH together with
OHT in MCF-10A cells upregulated the expression of
Ku70 but not Ku80 in comparison with OHT treatment
alone. The results suggest for the ability of TH to enhance
the capability of DNA double strand DNA repair through
the non-homologous end-joining repair pathway, especially
in the non-cancerous breast epithelial cells. We saw earlier
that TH dampened the DNA damage induced by OHT in
the noncancerous cells and this is corroborated by the
overexpression of Ku70 DNA repair enzyme in cells
treated with both TH and OHT compared to OHT treat-
ment alone. There are other proteins involved in double
strand DNA repair and it is currently not known whether
their expression would also be modulated by TH. Our
findings further suggest that TH is able to protect the
DNA integrity against the tamoxifen metabolite, OHT, in
non-cancerous cells and thereby preventing initiation of a
chain of reactions that transform these into cancer cells.
This differs from the action of the phytoestrogen, genis-
tein, which acts as an antioxidant that protected both nor-
mal and cancer cells against the genotoxic potential oftamoxifen [9]. Similarly, TH was shown to protect kerati-
nocytes from DNA damage induced by ultraviolet radi-
ation and the reduced pyrimidine dimer formation could
be the result of enhanced repair [35]. Tamoxifen is capable
of generating ROS in vitro [36] that would mediate the
OHT-induced DNA damage observed. The protective ef-
fect of TH against this DNA damage in the non-cancerous
cells could therefore be due to the ability of antioxidant
compounds present in the honey to quench the ROS gen-
erated. This is supported by the study of Beretta et al. [37]
that showed honey antioxidants protected cells against
free radical scavenging action and boost intracellular GSH
generation.
Conclusions
The current study shows that TH enhances OHT-induced
cytotoxicity and DNA damage in breast cancer cells while
affording protection to the non-cancerous cells. This in-
volves upregulation of double strand DNA repair enzymes
that may thus increase the efficiency of DNA repair mech-
anism in these cells, and thereby preserving the cellular
DNA integrity. The potential of TH to arrest breast cancer
growth while protecting normal breast epithelium should
be further explored in vivo. At least the use of TH may be
able to reduce the toxic effects of a chemotherapeutic
agent that could improve the quality of life for breast can-
cer patients.
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